Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell defects after cytoreductive therapy in man.

W Schreml, H P Lohrmann, B Anger

    Experimental Hematology
    |January 1, 1985
    PubMed
    Summary

    Chemotherapy can cause stem cell defects impacting blood cell production. This study monitored hematopoietic stem cells in patients, revealing long-term issues even when peripheral blood counts appear normal, suggesting careful monitoring is crucial.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Medical Rehabilitation in Gastrointestinal Oncology].

    Zentralblatt fur Chirurgie·2014
    Same author

    Integrated palliative care within a general hospital.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2000
    Same author

    Multiresidue chromatographic method for the determination of macrolide residues in muscle by high-performance liquid chromatography with UV detection.

    Journal of AOAC International·1999
    Same author

    Results of a European interlaboratory study for the determination of oxytetracycline in pig muscle by HPLC.

    The Analyst·1999
    Same author

    Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.

    Oncology·1997
    Same author

    Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients.

    Annals of hematology·1996

    Area of Science:

    • Hematology
    • Oncology
    • Stem Cell Biology

    Background:

    • Hematotoxicity is a major dose-limiting side effect of cytoreductive therapy.
    • Studying stem cell defects in humans post-therapy faces methodological challenges, including limitations in bone marrow sampling.
    • Ethical considerations restrict serial bone marrow specimen collection.

    Purpose of the Study:

    • To investigate the reaction of human hematopoietic stem cells and precursor pools to cytostatic chemotherapy regimens.
    • To assess the utility of peripheral blood colony-forming units (CFU) in monitoring long-term hematopoietic damage.
    • To develop methods for quantifying bone marrow stem cell defects.

    Main Methods:

    • Studied colony-forming unit granulocyte-macrophage (CFU-GM), CFU-erythroid (CFU-E), and burst-forming unit-erythroid (BFU-E) in bone marrow (BM) and peripheral blood (PB).
    • Utilized BM spicule morphometry and aspirate cellularity to develop a quantification index for BM data.
    • Monitored patients undergoing various adjuvant and palliative chemotherapy regimens for human cancer.

    Main Results:

    • Acute reactions of bone marrow stem cells and precursor pools mirrored findings in animal models.
    • Peripheral blood CFU-GM proved important for detecting long-term hematopoietic derangements in humans.
    • Observed stem cell defects in BM and PB not reflected in peripheral blood counts, particularly after nitrosourea treatment.
    • Detected prolonged stem cell derangements up to five years post-chemotherapy, especially after adjuvant therapy for breast cancer.

    Conclusions:

    • Peripheral blood CFU-GM is a valuable indicator of long-term hematopoietic stem cell damage in cancer patients.
    • Developed a novel index for quantifying bone marrow stem cell defects, aiding in understanding chemotherapy's impact.
    • Stem cell defects can persist long after treatment, even when peripheral blood counts normalize.
    • Recommends monitoring stem cell data for new chemotherapeutic regimens to mitigate early and late hematopoiesis side effects.

    Related Experiment Videos